The Biotech Growth Trust (LON:BIOG) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Shares of The Biotech Growth Trust PLC (LON:BIOG) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 958.04 ($12.06) and traded as low as GBX 850.45 ($10.70). The Biotech Growth Trust shares last traded at GBX 852 ($10.72), with a volume of 48,347 shares traded.

The Biotech Growth Trust Trading Down 0.4 %

The company has a current ratio of 0.59, a quick ratio of 0.00 and a debt-to-equity ratio of 11.02. The firm has a market capitalization of £243.41 million, a P/E ratio of 2.86 and a beta of 0.50. The firm has a 50-day moving average of GBX 869.02 and a two-hundred day moving average of GBX 958.04.

The Biotech Growth Trust (LON:BIOG) last posted its earnings results on Wednesday, November 27th. The company reported GBX 0.20 ($0.00) EPS for the quarter. The Biotech Growth Trust had a return on equity of 26.96% and a net margin of 95.33%.

Insider Buying and Selling at The Biotech Growth Trust

In related news, insider Julie Tankard purchased 1,022 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was bought at an average price of GBX 972 ($12.23) per share, with a total value of £9,933.84 ($12,503.26). Also, insider Nicola Shepherd purchased 1,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was bought at an average cost of GBX 846 ($10.65) per share, with a total value of £8,460 ($10,648.21). Over the last three months, insiders bought 6,222 shares of company stock worth $5,659,584. 0.71% of the stock is currently owned by insiders.

About The Biotech Growth Trust

The Biotech Growth Trust seeks capital appreciation through investment in the worldwide biotechnology industry. In order to achieve its investment objective, the Company invests in a diversified portfolio of shares and related securities in biotechnology companies on a worldwide basis. Performance is measured against the NASDAQ Biotechnology Index (sterling adjusted).